Increases in the TP53 mutation in African American men with tobacco-related cancers may be responsible for chemotherapy resistance and a poorer prognosis overall.
Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.
A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.
Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients—hair repigmentation—that may be a good response marker for this treatment.
Comprehensive sequencing for all breast cancer genes may provide complete relevant genetic information for Ashkenazi Jewish patients.
Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.
Researchers have discovered new associations between breast and ovarian cancer and genes that had not been previously detected, and which may help guide treatment decisions in the future.
Tumor samples from a single patient with melanoma provided researchers with new information about gene expression profiles that could inform immunotherapy treatments in the future.
A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.
Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.